Trazodone Monitoring Schedule: Labs, Exams, and What to Track at Every Life Stage

What Trazodone Is and Why Women Are Prescribed It

Trazodone is prescribed to more women than men. That fact matters clinically. Approximately 65% of trazodone prescriptions in the United States go to women, and the two most common reasons are depression and off-label insomnia. Understanding exactly what you are taking, how it behaves in your body, and what needs tracking over time is not optional background reading. It is the core of safe prescribing.

The drug was FDA-approved for major depressive disorder in 1981. Sleep use came later, driven by the drug's strong sedative properties at lower doses, and today the off-label insomnia indication accounts for a large share of prescriptions. A 2005 analysis by Mendelson in the Journal of Clinical Psychiatry reviewed the evidence base and found that while trazodone consistently improved sleep latency and sleep continuity in clinical practice, the randomized controlled trial evidence was thin and largely short-term. That evidence gap matters, and you deserve to know it.

How Trazodone Works: The Mechanism in Plain Language

Trazodone belongs to a class called serotonin antagonist and reuptake inhibitors (SARIs). It works through two complementary actions.

First, it blocks the serotonin transporter (SERT), which slows the removal of serotonin from synapses, much like SSRIs do, but less potently. Second, and more distinctively, it antagonizes specific serotonin receptor subtypes, particularly 5-HT2A and 5-HT2C receptors. Blocking 5-HT2A receptors reduces anxiety and promotes slow-wave sleep. That receptor blockade is the primary reason trazodone is sedating at low doses, even before its antidepressant effect kicks in at higher doses.

It also antagonizes histamine H1 receptors and alpha-1 adrenergic receptors. The alpha-1 blockade is why orthostatic hypotension (a sudden blood pressure drop when you stand up) is a real concern, particularly in older women and women on antihypertensives.

How Sex-Specific Physiology Changes the Pharmacology

Women metabolize trazodone somewhat differently than men. Trazodone is primarily metabolized by CYP3A4, and CYP3A4 activity fluctuates across the menstrual cycle, with higher activity in the luteal phase driven by progesterone. This means trazodone may clear faster in the week before your period, potentially reducing its sedative effect right when sleep disruption from premenstrual symptoms is already peaking. This is not well studied with trazodone specifically, but the CYP3A4 fluctuation is established physiology.

Body fat percentage, which is on average higher in women, also affects drug distribution. Trazodone is moderately lipophilic, so a higher fat-to-lean ratio can extend its half-life and intensify next-morning sedation ("hangover effect") in women who carry more adipose tissue.

The Monitoring Schedule: A Stage-by-Stage Framework

Most published monitoring guidance for trazodone is written around the average adult, which in clinical trial populations has historically meant a middle-aged man. The framework below is organized specifically around the stages of a woman's life, because your monitoring priorities genuinely differ depending on where you are hormonally and reproductively.

Before You Start: Baseline Assessments

Before your first dose, a responsible prescriber should document the following.

Blood pressure and heart rate (standing and seated). Trazodone's alpha-1 blockade means orthostatic hypotension is a real risk. Knowing your baseline allows you and your clinician to detect a meaningful change. Women with a baseline systolic pressure below 110 mmHg deserve particular attention here.

Baseline ECG. This is not universally required by labeling, but trazodone prolongs the QTc interval at higher doses, and women already have longer baseline QTc intervals than men, on average 20 milliseconds longer after puberty. That sex difference, documented in multiple cardiac electrophysiology studies, means women are at modestly higher risk of drug-induced QT prolongation. An ECG at baseline is prudent if you have a personal or family history of arrhythmia, are taking other QT-prolonging medications, have hypokalemia, or have thyroid disease affecting cardiac conduction.

Liver function tests (LFTs). Trazodone is metabolized hepatically. Rare but documented cases of trazodone-associated hepatotoxicity exist in the literature. A baseline ALT and AST gives you and your clinician a reference point. This is especially relevant if you have PCOS with metabolic liver disease (non-alcoholic fatty liver disease, now called metabolic dysfunction-associated steatotic liver disease), which affects a substantial minority of women with PCOS.

Depression and sleep symptom baseline scores. Use a validated tool. The PHQ-9 for depression and the Insomnia Severity Index (ISI) are both free and take under five minutes. Tracking scores over time is the only way to know whether the drug is working.

Medication reconciliation for interactions. CYP3A4 inhibitors, including fluconazole (commonly prescribed to women for vaginal yeast infections), some hormonal contraceptives, and grapefruit, can raise trazodone blood levels significantly. CYP3A4 inducers such as rifampicin can drop them. Document every supplement and medication before starting.

Weeks 1 Through 4: The Early-Adjustment Window

The first four weeks carry the highest risk of adverse events and the lowest likelihood of seeing full antidepressant effect (which typically takes 4 to 6 weeks at therapeutic doses). Your monitoring should be more frequent here.

Every 1 to 2 weeks: A brief check-in, which can be a telehealth visit or a structured symptom questionnaire, should capture:

• Orthostatic symptoms (dizziness, lightheadedness when standing)
• Sedation severity and next-morning grogginess, which affects driving safety
• Any new or worsening suicidal ideation (the FDA black box warning on all antidepressants applies to trazodone, especially in adults under 25)
• Sleep quality change using the ISI or a simple sleep diary
• Gastrointestinal symptoms (nausea, dry mouth)

Blood pressure recheck at week 2 to 4 if you reported orthostatic symptoms at baseline or if you are taking antihypertensives.

Menstrual cycle tracking. If you are in your reproductive years, note whether trazodone affects your cycle. Serotonergic drugs can raise prolactin, and sustained hyperprolactinemia can suppress LH pulsatility, potentially disrupting ovulation. This effect is modest with trazodone compared with antipsychotics, but if you are trying to conceive, it is worth flagging any cycle irregularity to your prescriber early.

Months 1 Through 3: Stabilization Monitoring

Monthly PHQ-9 or ISI. Quantifying response matters. If PHQ-9 has not dropped by at least 5 points after 8 weeks at a therapeutic dose, your prescriber should revisit the diagnosis, dose, or drug choice.

Repeat LFTs at month 1 to 3 if you had any baseline elevation, have PCOS-associated metabolic liver disease, drink alcohol regularly, or are on other hepatotoxic medications. This is not a labeled requirement, but it reflects conservative clinical practice given the hepatotoxicity case reports.

Weight and metabolic parameters. Trazodone is not weight-neutral. Sedation-driven reductions in activity and mild antihistaminergic appetite stimulation can contribute to weight gain over months. For women with PCOS, obesity, or a history of metabolic syndrome, a weight check and fasting glucose at the 3-month mark is reasonable. Women in perimenopause, who are already at elevated metabolic risk from declining estradiol, should be especially attentive here.

Months 3 Through 12: Ongoing Maintenance Monitoring

Once you are stable, monitoring can be spaced out.

Every 3 to 6 months: PHQ-9 or ISI, blood pressure, and a brief symptom review.

Annual: Repeat LFTs if you are on long-term therapy and have any metabolic or hepatic risk factors. Repeat ECG if you have developed new cardiac risk factors or if your dose has increased above 300 mg daily.

Bone health note for long-term use. Emerging data suggest that chronic use of serotonergic antidepressants may modestly reduce bone mineral density by interfering with serotonin signaling in osteoblasts. For women who are perimenopausal or postmenopausal and already experiencing accelerated bone loss, this is a relevant long-term consideration. A DEXA scan is not routinely added for trazodone alone, but it should factor into your broader bone health conversation if you are using the drug long-term and are past your early 40s.

Life-Stage-Specific Monitoring: From Reproductive Years to Post-Menopause

Reproductive Years (Roughly Ages 18 to 40)

The primary monitoring additions in this stage center on menstrual function, ovulation, and contraceptive status.

Track your cycle from the first month. Any new irregularity, missed periods, or galactorrhea (unexpected nipple discharge) should prompt a serum prolactin check and a conversation about whether trazodone is the contributing factor.

If you are sexually active and not planning pregnancy, your prescriber should document your contraceptive method at initiation. Trazodone is not a teratogen in the sense of having a defined risk level that mandates contraception (unlike valproate or isotretinoin), but the limited human pregnancy data and FDA Pregnancy Category C status mean unintended pregnancy while on trazodone carries uncertainty. Reliable contraception is the sensible default.

Trying to Conceive (TTC)

This is the stage where the evidence gap is most glaring and honesty matters most. There are no large prospective trials examining trazodone's effect on fertility outcomes in women. The theoretical concern is modest: serotonin-driven prolactin elevation could interfere with LH surges and ovulation in a small subset of women. If you are actively trying to conceive and not getting pregnant within 6 months of trazodone initiation, baseline prolactin and a cycle day 21 progesterone check are reasonable steps before attributing the problem to other causes.

Your reproductive endocrinologist and prescribing clinician should communicate directly. Depression and sleep disorders themselves impair fertility through HPA-axis dysregulation, so discontinuing an effective medication without a plan is not automatically the safer choice.

Pregnancy

Trazodone carries FDA Pregnancy Category C, meaning animal studies have shown fetal harm, but controlled human data are absent. The drug should be used during pregnancy only if the benefit to you clearly outweighs the potential risk to the fetus. This is a conversation, not a blanket prohibition.

The limited observational data do not show a clear signal for major congenital malformations, but the studies are too small to rule one out. Neonatal effects including jitteriness and mild respiratory depression have been reported with third-trimester serotonergic drug exposure, consistent with what is seen with SSRIs. These are generally transient.

If you become pregnant while taking trazodone: Do not stop abruptly. Abrupt discontinuation can cause withdrawal symptoms, and untreated depression in pregnancy carries its own significant risks to you and your baby, including preterm birth and impaired maternal bonding. Discuss a supervised taper or continuation with your OB and prescribing clinician together. ACOG Practice Bulletin 92 provides a framework for managing psychiatric medications in pregnancy.

Monitoring during pregnancy should include: standard antenatal labs, fetal anatomy ultrasound at 18 to 20 weeks, and neonatal observation for withdrawal symptoms if the drug is used into the third trimester.

Postpartum and Lactation

Trazodone is detectable in breast milk. Published case reports and small pharmacokinetic studies suggest relative infant dose is low, generally below 5% of the maternal weight-adjusted dose, which is the threshold often used clinically to consider a drug compatible with breastfeeding. Infants have immature hepatic metabolism and trazodone may accumulate more than pharmacokinetic models predict.

If you choose to breastfeed while on trazodone, monitor your infant for sedation, poor feeding, and reduced responsiveness. Timing the dose right after a feeding (and before the longest sleep interval) minimizes peak exposure in milk.

Postpartum insomnia and depression are both common, and trazodone is sometimes chosen precisely because it addresses both. The decision to use it while breastfeeding is one your clinician and you make together with full information, not one with a clean yes or no answer.

Perimenopause (Roughly Ages 40 to 55)

Perimenopause is a high-prescribing window for trazodone because sleep disruption is near-universal and depression rates rise significantly during this stage. A longitudinal analysis in the SWAN cohort found that perimenopausal women had significantly elevated odds of first-onset depression compared with premenopausal women, underscoring how common mood and sleep symptoms are in this stage.

Several pharmacology considerations are specific to perimenopause.

Declining estradiol reduces CYP3A4 activity variability, which may slightly increase trazodone exposure compared with reproductive years. Starting at 50 mg at bedtime rather than jumping to 100 mg is conservative and appropriate.

Vasomotor symptoms (hot flashes, night sweats) are often the proximate cause of waking, not insomnia per se. Trazodone improves sleep architecture but does not address hot flashes. If vasomotor symptoms are the root cause of your sleep disruption, hormone therapy or an FDA-approved non-hormonal option may be more targeted than trazodone alone.

Blood pressure monitoring is more important in perimenopause because cardiovascular risk begins rising as estradiol declines. Alpha-1 blockade from trazodone adds an orthostatic risk on top of this.

Post-Menopause

Long-term trazodone use in post-menopause warrants attention to three things: bone density (as noted above), cognitive effects (sedation that impairs next-day function or contributes to fall risk in women over 65), and cardiac monitoring given the higher baseline QTc prolongation risk in older women.

The American Geriatrics Society Beers Criteria does not list trazodone as an outright drug to avoid in older adults, unlike many sedative-hypnotics, but notes that sedating antidepressants in older women require attention to fall risk, orthostatic hypotension, and anticholinergic burden. Annual fall-risk assessment becomes part of the monitoring framework after age 65.

Drug Interactions That Require Specific Monitoring in Women

Women are prescribed more medications than men on average and carry a correspondingly higher polypharmacy burden. Several drug interactions with trazodone are particularly common in women's health practice.

Hormonal contraceptives. Some combined oral contraceptives inhibit CYP3A4 and may raise trazodone levels. If you start or stop oral contraceptives while on trazodone, watch for changes in sedation intensity.

Fluconazole (Diflucan). This antifungal, frequently prescribed for vulvovaginal candidiasis, is a strong CYP3A4 inhibitor. Fluconazole co-administration can raise trazodone plasma levels substantially. A single-course treatment is unlikely to cause a clinical problem, but if you are on repeated courses, inform your prescriber.

SSRIs and SNRIs. Trazodone is sometimes added to an SSRI for sleep augmentation. This combination increases serotonin syndrome risk. Serotonin syndrome in mild form can look like agitation, diaphoresis, and tachycardia. Know the signs.

MAOIs. Combining trazodone with a monoamine oxidase inhibitor is contraindicated. The combination can precipitate severe serotonin syndrome. Allow at least 14 days after stopping an MAOI before starting trazodone.

Pregnancy and Lactation: The Full Picture

Pregnancy category: C. Animal reproductive studies showed adverse fetal effects; there are no adequate, well-controlled studies in pregnant women.

Human pregnancy data: Limited. Large registry studies that have examined SSRIs do not consistently include trazodone in sufficient numbers for independent risk estimates. The existing observational data do not show a clear major malformation signal, but absence of evidence is not evidence of absence.

First-trimester exposure: If you took trazodone before knowing you were pregnant, do not panic. Discuss findings from current registry data with your OB. Stopping abruptly is not automatically safer than continuing with supervision.

Third-trimester considerations: Neonatal adaptation syndrome, characterized by jitteriness, feeding difficulty, and mild respiratory symptoms, has been reported. Neonatal monitoring for 48 to 72 hours after birth is appropriate if you used trazodone through the third trimester.

Lactation: Relative infant dose is low based on available case data. Monitor your infant for sedation and feeding changes. The LactMed database at NIH is the most current resource your clinician should reference for updated transfer data.

Contraception: No mandatory contraceptive requirement exists for trazodone the way it does for isotretinoin or valproate. However, given Category C status and the absence of reassuring human data, reliable contraception in women of reproductive age who do not wish to conceive is the prudent standard, and this should be explicitly documented in your medical record.

Who This Drug Is and Is Not Right For

Women Who Are Typically Good Candidates

• Women with depression and comorbid insomnia who want to address both with a single agent
• Perimenopausal women with sleep-maintenance insomnia who are not candidates for or who decline hormone therapy
• Women who need a non-benzodiazepine, non-controlled-substance sleep aid with lower dependency risk than Z-drugs (zolpidem, eszopiclone)
• Women with PCOS and depression who cannot tolerate weight gain from certain antidepressants (trazodone's weight impact is generally less than mirtazapine)

Women Who Need Additional Caution or Alternative Options

• Women with known QTc prolongation or on multiple QT-prolonging drugs
• Women who are pregnant, especially in the first trimester, without a clear clinical necessity
• Women over 65 at high fall risk, given orthostatic hypotension and residual sedation
• Women with severe hepatic impairment, as trazodone's hepatic clearance will be impaired
• Women actively trying to conceive who develop cycle irregularities or elevated prolactin on trazodone

A Practical Monitoring Calendar

The table below summarizes the minimum recommended monitoring for a woman on trazodone for either depression or sleep.

| Timepoint | Assessment | |---|---| | Baseline | Blood pressure (seated + standing), resting heart rate, LFTs, ECG if cardiac/QTc risk, PHQ-9 or ISI, medication/supplement list, menstrual cycle documentation, pregnancy test if reproductive age | | Week 2 | Symptom check, orthostatic symptoms, sedation severity, suicidality screen | | Week 4 | Blood pressure recheck, PHQ-9 or ISI, menstrual cycle check | | Month 3 | LFTs (if baseline risk), weight, fasting glucose (if metabolic risk), PHQ-9 or ISI, prolactin if cycle irregularity | | Month 6 | Blood pressure, PHQ-9 or ISI, symptom review | | Annually | LFTs (long-term use with metabolic risk), ECG (if dose above 300 mg or new cardiac risk), fall risk screen (if age <65 not applicable; if 65+, include formal assessment), DEXA consideration if perimenopausal or postmenopausal on long-term therapy |